Friday, August 02, 2024 9:50:16 AM
Investor082,
All those who will want to get out had a chance to vote at the ASM. Barely any budge off of previous vote counts so show me the impact of those who will choose to get out early other than to help some others cover short positions or take up new long positions in a company that will be the future of cancer treatment while those who bail will miss out unless you are simply talking about a timed trading strategy that anticipates no additional backup news for a while. In that case that trade is just a calculated risk, not a permanent exit; ).
I would love to see the 7 market makers kept out of the action by the time approval is announced and a big investor step up between now and then to benefit from NWBO’s new position with an approved treatment to help leverage a likely partnership deal that might otherwise be held up by unfavorable terms because NWBO doesn’t have financial stability in place for its investors. Then I would love to see what happens with other big pharma offers once Flaskworks comes on line enough to be used in trials. Once financing is taken care of I would love to see what improved DCVax Direct does in months instead of years and who wouldn’t love to see the tables turn as big pharma attempts at catching up fall short and they find themselves needing to approach NWBO as talent gets drawn away from them and to the new cancer treatment leader. Yep, lots of good reasons to stick around for the show because having a big checkbook will definitely come in handy if anyone wants a part of what is coming sooner or later depending on the moves by those with the money. Best wishes.
All those who will want to get out had a chance to vote at the ASM. Barely any budge off of previous vote counts so show me the impact of those who will choose to get out early other than to help some others cover short positions or take up new long positions in a company that will be the future of cancer treatment while those who bail will miss out unless you are simply talking about a timed trading strategy that anticipates no additional backup news for a while. In that case that trade is just a calculated risk, not a permanent exit; ).
I would love to see the 7 market makers kept out of the action by the time approval is announced and a big investor step up between now and then to benefit from NWBO’s new position with an approved treatment to help leverage a likely partnership deal that might otherwise be held up by unfavorable terms because NWBO doesn’t have financial stability in place for its investors. Then I would love to see what happens with other big pharma offers once Flaskworks comes on line enough to be used in trials. Once financing is taken care of I would love to see what improved DCVax Direct does in months instead of years and who wouldn’t love to see the tables turn as big pharma attempts at catching up fall short and they find themselves needing to approach NWBO as talent gets drawn away from them and to the new cancer treatment leader. Yep, lots of good reasons to stick around for the show because having a big checkbook will definitely come in handy if anyone wants a part of what is coming sooner or later depending on the moves by those with the money. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
